Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab
2011

Successful Treatment of Kidney Disease Linked to Blood Cancer

Sample size: 1 publication Evidence: low

Author Information

Author(s): Arampatzis Spyridon, Giannakoulas Nikolaos, Liakopoulos Vassilios, Eleftheriadis Theodoros, Kourti Panagiota, Karasavvidou Foteini, Matsouka Panagiota, Stefanidis Ioannis

Primary Institution: University of Thessaly, Larissa, Greece

Hypothesis

Can chemotherapy effectively treat focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia?

Conclusion

Chemotherapy with fludarabine, cyclophosphamide, and rituximab successfully resolved nephrotic syndrome in the patient with CLL.

Supporting Evidence

  • The patient had a significant reduction in urinary protein excretion after treatment.
  • Bone marrow biopsy showed normal haematopoietic cells after therapy.
  • The patient remained in complete remission 28 months after diagnosis.

Takeaway

A man with a rare kidney disease caused by blood cancer got better after receiving special chemotherapy.

Methodology

The patient was treated with fludarabine, cyclophosphamide, and rituximab over six cycles, with monitoring of kidney function and blood counts.

Limitations

The study is based on a single case, and further studies are needed to confirm the findings.

Participant Demographics

A 53-year-old Caucasian man.

Digital Object Identifier (DOI)

10.1186/1471-2369-12-33

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication